LAWRENCE LAPOINTE, PhD
Chief Executive Officer, Director, Co-Founder
Lawrence LaPointe has nearly two decades of senior management experience (General Manager, CTO, COO, CEO) developing, growing and selling companies in the field of cancer screening. Dr. LaPointe has an unbroken track record of increasing shareholder value each year of his career including co-founding Enterix Inc. which was built and sold for an enterprise value more than $50M. He has capital raising experience from private, venture and commercial funders totaling more than $40 million and global licensing and sales experience including US, EU, Asia, ANZ. Dr. LaPointe is a well published research scientist and holds numerous patents in the fields of biomarker discovery, cancer detection and molecular diagnostics. He holds a B.Sc. in Biology from Florida State University and a Ph.D. in Bioinformatics from Flinders University, Australia.
Chief Financial Officer
Roger Moody brings to Clinical Genomics a proven track record in leading financial operations and raising capital for rapidly growing companies. Prior to joining Clinical Genomics, Roger served as Chief Executive Officer and Board Director of GlySure Limited, a leading UK based company specializing in continuous glucose monitoring (CGM) for patients under critical care. During his tenure, Moody strategically repositioned GlySure in the rapidly evolving home diabetes market while also establishing an economic value model for hospital adoption. Roger has also held leadership positions in a number of growth companies, including the role of Chief Financial Officer at Nanosphere, Inc and Medsn, Inc. where he served as CFO prior to becoming the Vice President, Business Development and then Chief Operating Officer. His extensive experience in managing rapid growth and delivering value to investors will be instrumental in achieving Clinical Genomics’ commercial objectives. Roger earned a Bachelor of Science in Finance from Syracuse University and a Master of Business Administration with an emphasis in Finance from the Graduate School of Business at the University of Chicago.
TADD LAZARUS, MD
Chief Medical Officer
Dr. Tadd Lazarus is an experienced Chief Medical Officer with over 20 years in the biotechnology and IVD industries and a strong background in clinical trials, regulatory affairs and medical advocacy. Dr. Lazarus previously served as Sr. Vice President and Chief Medical Officer for Luminex, focusing on the strategic clinical direction for the company. He was Chief Medical and Head of Medical & Scientific Affairs, Reimbursement, and Public Policy at Qiagen from 2013 through 2016. In 2010, Dr. Lazarus was at Gen-Probe Inc., (now Hologic), as Chief Medical Officer and VP of Clinical Affairs, where he was responsible for a 42-person team dedicated to clinical trials. He began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as Director of Medical and Scientific Affairs, and then as the North American Medical Director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology lines of business.
Dr. Lazarus has a Bachelor of Science in Biology & Physiology from Marlboro College and a Medical Degree from Ross University School of Medicine.
Chief Operating Officer
Ms. Huard has more than thirty years of experience in laboratory operations and lab informatics with a range of laboratories. Laurie previously served as Vice President of Operations at Helomics, Inc., a molecular diagnostics company, as a Laboratory Director for a large integrated hospital laboratory, and as a Laboratory Information Systems Manager. In addition, she has operated a lab informatics consulting practice for over ten years and has worked with numerous clients ranging from a nationally-recognized academic medical system laboratory (where she oversaw the implementation of a new LIS system) to large and small independent laboratory companies. She has extensive experience in all aspects of laboratory operations and lab informatics, including the selection, implementation and operation of a number of lab IT platforms in various clinical environments including clinical chemistry, microbiology, anatomic pathology and molecular diagnostics. Ms. Huard has a B.S. from Louisiana Tech University and an M.A. from Georgetown University.
President, In Vitro Diagnostics (IVD)
Mark Boyle has more than 26 years of commercial experience at leading global IVD and life science companies. He previously served as Vice President at QIAGEN Inc. where he successfully led the company’s global business portfolio in tuberculosis management and helped achieve more than $100 million in revenues. He also served as President of Cellestis Inc., where he successfully launched and led the adoption of a screening test for tuberculosis, played a critical role in the company reaching profitability and was instrumental to its acquisition and successful integration into QIAGEN. Mark has also held the role of General Manager for the U.K. subsidiary of Diagnostic Systems Laboratories Inc., an IVD manufacturer, as well as sales and marketing positions with two Australian biotech start-ups. He has a B.Sc. in Biochemistry and Microbiology, and a Graduate Certificate in Management from the University of Adelaide, Australia.
Vice President Reimbursement
Mr. Bruce has over 25 years of experience advising and serving in senior management roles (CFO, COO, CEO, Director) for a range of private and public companies. Among his previous positions, he served as COO and VP of Reimbursement at Enterix and led the company’s efforts to secure regulatory approvals and reimbursement for the InSure FIT test. BA Princeton University; MBA Yale University
Vice President, Sales and Marketing
Karol Ford is an accomplished sales professional with more than 20 years of progressive leadership experience specializing in national account management, business development and sales and marketing management. She has a proven track record of successfully working with development stage companies from the ground up, leading the growth and expansion of sales teams to generate positive revenue. Karol previously held positions of increasing responsibility with Progenity, a private genetics reference laboratory, where she successfully launched a new division and sales force to promote genetic carrier screening for intellectual disabilities and developmental delays. Additionally, she served in a variety of sales leadership positions with Eragen Biosciences, Dako and Qiagen (formerly known as Digene Corporation) Karol has a B.S. from The University of Phoenix.
Vice President Regulatory Affairs
Michele Houldsworth has deep experience in Quality Assurance specializing in system design and development for compliance in small to medium enterprises. She is a certified lead auditor of quality systems and medical devices and has hands on experience in all phases of product development from research to commercialisation of medical devices and IVDs (Class II, III). Her experience includes successful achievement of ARTG listing and CE-marking, experience in technical file, design dossier and 510k file preparation for AU, EU, US and Chinese markets. Ms. Houldsworth is expert in process validation including sterilization and biocompatibility. BE MBiomedE (Mech; Honours Class I; University of New South Wales; 2007).
TANIA OBRANOVICH, B.SC. (HONS), PhD, LLB
Vice President Intellectual Property, Legal Affairs & Compliance
Dr. Obranovich has more than 20 years private practice experience in developing and managing global IP portfolios in the biotechnology sector, with a focus on molecular, cellular and genomic technologies as they relate to diagnostics and therapeutics. She practices as both a lawyer and a patent attorney and spent ten years as a partner at a top tier Australian intellectual property firm. Dr. Obranovich was extensively involved in the Australian Federal Government policy issues that arose in light of the Myriad Genetics gene patents and she also speaks widely in relation to IP issues. She is admitted as a Barrister and Solicitor of the Supreme Court of Victoria and the Federal and High Courts of Australia. She is also registered as a patent and trademarks attorney in both Australia and New Zealand. Prior to these roles, she completed a post-doctoral fellowship in immunology and lectured in immunology at Monash University. Dr. Obranovich teaches patent law at Melbourne University, Monash University and RMIT University. She received her B.Sc. (Hons), LL.B., and Ph.D. (Immunology) degrees from Monash University.
SUSANNE K. PEDERSEN, PhD
Vice President Science & Innovation (CSO), Co-founder
Susanne Pedersen has deep commercial experience focused on biomarker discovery and validation including product concept to successful commercial launch. IVD assay expertise includes molecular diagnostics, proteomics, and immunoassays in esoteric pathology labs as well as point of care testing. Since 2010, her concentrated expertise has been in epigenetics and cell free DNA measurements for cancer detection. Dr. Pedersen is the Inventor of biomarker discovery patents and has a successful track record building cross-functional teams that meet commercial milestones including scale up. B.Sc. (Cell Biology; Southern University of Denmark, 1996); Ph.D. (Molecular Biology; Southern University of Denmark; 2000).